Cardiff Oncology Q2 2023 Earnings Report

Cardiff Oncology EPS Results

• Actual EPS: -$0.25
• Consensus EPS: -$0.27
• Beat/Miss: Beat by +$0.02
• One Year Ago EPS: N/A

Cardiff Oncology Revenue Results

• Actual Revenue: $0.11 million
• Expected Revenue: $0.08 million
• Beat/Miss: Beat by +$30.00 thousand
• YoY Revenue Growth: N/A

Cardiff Oncology Announcement Details

• Quarter: Q2 2023
• Date: 8/9/2023
• Time: N/A
• Conference Call Date: Wednesday, August 9, 2023
• Conference Call Time: 7:00AM ET

Cardiff Oncology (NASDAQ:CRDF) is a clinical-stage biotechnology company focused on developing personalized combination therapies for the treatment of cancer. By leveraging its proprietary OncoSignature platform, the company integrates genomic, transcriptomic and proteomic data to predict synergistic interactions between immuno-oncology agents and targeted drugs. Cardiff Oncology’s approach aims to move beyond single-agent therapies by identifying optimal regimens that address the complexity and heterogeneity of tumor biology.

The company’s pipeline includes multiple combination therapy candidates in clinical trials for various solid tumors and hematological malignancies. Its lead programs explore the use of checkpoint inhibitors in tandem with small-molecule inhibitors and monoclonal antibodies, with early data demonstrating potential benefits in tumor response rates. Cardiff Oncology also collaborates with academic medical centers and contract research organizations to accelerate the design and execution of its clinical studies.

Founded in 2012 and headquartered in San Diego, California, Cardiff Oncology has expanded its research and development operations across the United States. Since inception, the company has built a multidisciplinary team of scientists, clinicians and data analysts dedicated to precision oncology. In recent years, Cardiff Oncology has entered strategic partnerships to enhance its translational research capabilities, drawing on expertise in bioinformatics and molecular diagnostics.

Cardiff Oncology is led by an executive team with extensive experience in oncology drug development, regulatory affairs and commercial strategy. The company’s leadership includes veterans from major pharmaceutical and biotechnology firms, underscoring its commitment to advancing innovative cancer therapies. With a focus on personalized medicine and data-driven insights, Cardiff Oncology seeks to deliver new combination treatments that improve outcomes for patients with difficult-to-treat cancers.